PCM
AERI

Palisade Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Palisade Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,000
Closed -$651K – 477
2018
Q1 		$651K Buy
12,000
+1,900
+19% +$106K 0.02% 365
2017
Q4 		$603K Buy
10,100
+5,850
+138% +$355K 0.02% 369
2017
Q3 		$207K Buy
4,250
+207
+5% +$11.3K 0.01% 417
2017
Q2 		$212K Buy
+4,043
New +$188K 0.01% 420

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Palisade Capital Management's AERI Position: Q2 2018 in Review

Palisade Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2018, closing a stake of 12,000 shares — an estimated $651K sold.

Palisade Capital Management first reported a position in AERI in Q2 2017 and held it in 4 quarters. The position peaked at $651K in Q1 2018. 175 funds tracked by Wall St. Rank hold AERI as of Q2 2018.

  • Palisade Capital Management reported no remaining Aerie Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Palisade Capital Management sold 12,000 Aerie Pharmaceuticals shares in Q2 2018, an estimated $651K.
  • Palisade Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Palisade Capital Management's Aerie Pharmaceuticals position peaked at $651K in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2018.

Based on Palisade Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.